Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

IMNN-001

Vaccine (DNA plasmid) · Immune activation · developed by Imunon

Phase 3 Most advanced trial
IMNN Developer
2 Registered trials

What is IMNN-001?

IMNN-001 is a plasmid DNA vaccine encoding interleukin-12 formulated in a PEG-PEI-cholesterol lipoplex for intraperitoneal delivery. It activates the immune system by promoting natural killer cell activation and cytotoxic T-cell responses against tumor cells. It is studied in epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
GEN-1
Drug type
Vaccine (DNA plasmid)
Mechanism
Immune activation
Pathways
immune activation, natural killer cell activation, interferon-gamma secretion, cytotoxic T-cell response
Therapy area
Oncology
Developer
Imunon (IMNN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06915025 Phase 3 Epithelial Ovarian Cancer Recruiting IMNN
NCT03393884 Phase 1/2 Epithelial Ovarian Cancer Active not recruiting IMNN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Epithelial Ovarian CancerFallopian Tube CancerOvarian CancerPrimary Peritoneal CancerPrimary Peritoneal Carcinoma

More from Imunon

IMNN-101 Phase 1/2 Lyso-Thermosensitive Liposome Doxorubicin Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IMNN page.

Follow IMNN, the company behind IMNN-001

See IMNN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMNN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.